About Ionetix
Ionetix is a Healthcare company based in San Francisco (United States) founded in 2009. Superconducting cyclotrons for PET radioisotopes are developed by Ionetix. Ionetix has raised $61.08 million across 4 funding rounds from investors including Lilly and Tees River. Its chief executive, as recorded, is Kevin Cameron. Ionetix offers products and services including N-13 Ammonia and Targeted Alpha Therapy. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Screening Devices. Its legal entity is IONETIX CORPORATION. Its competitors include ImaginAb, Innovate Biopharma and Progenics; 2 of its 3 listed competitors have raised funding.
Company details
Ionetix Corporation was founded in 2009 and is headquartered in San Francisco, United States. Operations focus on the development of superconducting cyclotrons designed for on-site production of positron emission tomography (PET) radioisotopes. The ION-12 system automates the generation of N-13 ammonia, an FDA-approved radiopharmaceutical utilized in myocardial perfusion PET studies to detect coronary artery disease. This technology is applied within the medical imaging sector.
- Headquarters San Francisco, United States
- SectorsHealthcare
- Email••••••••
- Website ionetix.com
- Social LinkedIn X
- Legal Name Ionetix Corporation
- Total Equity Funding$61.08M (USD)
in 4 rounds
- InvestorsLilly
& 1 more
Products & Services of Ionetix
Ionetix offers a comprehensive portfolio of products and services, including N-13 Ammonia and Targeted Alpha Therapy.
Radiopharmaceutical for cardiac PET imaging diagnostics.
Uses alpha radionuclides for targeted cancer therapy applications.
Funding Insights of Ionetix
Ionetix has successfully raised a total of $61.08M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $61.08M
- Total Rounds 4
- First Round $23.8M
(Mar 2018)
- Investors Count 2
All 4 funding rounds of Ionetix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $30M | Post-IPO | – | – | – |
| Aug 2024 | Series C | – | Lilly | ||
| May 2020 | $37.29M | Series C | – | – | – |
| Mar 2018 | $23.8M | Series B | – | – | – |
2 investors in total: 2 institutional.
Investors in Ionetix
Ionetix has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Lilly and Tees River.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
Invests in sustainable returns from global economy's Net Zero transition for professional investors. | 2019 | teesriver.co.uk | Gerrards Cross, United Kingdom |
Investor details for Ionetix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ionetix
25 people are tracked at Ionetix (18 in leadership, 7 in team).
| Name | Role | Group |
|---|---|---|
Kevin Cameron | CEO | Leadership |
Kevin J. Cameron | CEO | Leadership |
Anthony Stagnolia | COO | Leadership |
Peter Burke | VP, Sales & Marketing | Leadership |
Andy Steele | Quality Assurance Program Director | Leadership |
Nick Freiburger | Sr. Director - Alpha Operations | Leadership |
Dominica Palacio | Vice President of Administration | Leadership |
Alexander Yordanov, Ph.D. | Director, CMC Product Development | Leadership |
Brice Furr | Sr. Director Of Engineering | Leadership |
Jill Wilson | Vice President of Regulatory Affairs & Quality Assurance | Leadership |
Mark Leuschner | VP | Leadership |
Phieu Phun | Chief Financial Officer | Leadership |
Rachel Seidel | Vice President Business Processes And Operational Excellence | Leadership |
Michael Barr | Sr. Director, Construction Management | Leadership |
Jim Porter | Director Of Business Expansion Planning | Leadership |
Christopher Shreves | Vice President, Site Operations | Leadership |
Brian G. Barsamian | Director of Government and National Accounts | Leadership |
John Vincent | VP, Engineering & New Product Development | Leadership |
Renan Fontus | Senior Manufacturing Engineer | Team |
Myla Vanlandingham | Pharmaceutical National Account Manager And Market Analyst | Team |
5 more people are available in the full profile.
Complete people profiles for Ionetix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ionetix
3 dated milestones of Ionetix across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Ionetix is founded.
- Funding First funding round of $23.8M.
- Funding Latest funding round, Post-IPO,.
Competitors of Ionetix
Ionetix has 3 listed competitors in our database, 2 of them funded. They include ImaginAb, Innovate Biopharma and Progenics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| imaginab.com | 2007 | Los Angeles, United States | $59.64M | 17 | ImaginAb is focused on developing advanced immuno-oncology imaging technologies. | |
| innovatebiopharma.com | 2012 | Raleigh, United States | $48.58M | Small molecule drugs and imaging agent for GI disorders | ||
| progenics.com | 1988 | United States | 53 | Imaging compounds & targeted radiotherapies to detect and treat prostate cancer. |
Detailed competitors of Ionetix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ionetix
The website of Ionetix (ionetix.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▼ 20.6% vs previous month
Top companies in Imaging Diagnostics
3 companies that operate in the same segment as Ionetix (Imaging Diagnostics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Handheld ultrasound devices are developed for whole-body medical imaging. | 2011 | Guilford, Connecticut, United States | USD 350 M | USD 97.61 M | 464 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 | ||
Ultrasound images are analyzed via AI-based software provided by Exo. | 2015 | Redwood City, California, United States | USD 463.39 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ionetix
Complete news archive for Ionetix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ionetix
Ionetix was founded in 2009 and raised its 1st funding round 9 years after it was founded.
Ionetix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Kevin Cameron is the CEO of Ionetix, as recorded in our data.
Ionetix is a funded company, having raised a total of $61.08M across 4 funding rounds to date. The company's 1st funding round was a Series B of $23.8M, raised on Mar 2018.
Ionetix Corporation was founded in 2009 and is headquartered in San Francisco, United States. Operations focus on the development of superconducting cyclotrons designed for on-site production of positron emission tomography (PET) radioisotopes. The ION-12 system automates the generation of N-13 ammonia, an FDA-approved radiopharmaceutical utilized in myocardial perfusion PET studies to detect coronary artery disease. This technology is applied within the medical imaging sector.
Ionetix's top competitors include ImaginAb, Innovate Biopharma and Progenics.
Ionetix offers N-13 Ammonia and Targeted Alpha Therapy.
Ionetix has 2 investors. Key investors include Lilly, and Tees River.
Ionetix operates through Ionetix Corporation.